Sinovac Begins Phase 1 Trial of its COVID-19 Vaccine Candidate

Sinovac Biotech has begun a phase 1 trial in China to evaluate the safety of a potential  COVID-19 vaccine.

The trial in 144 healthy adults will evaluate Sinovac’s chemically inactivated coronavirus vaccine with Dynavax’s CpG 1018 adjuvant.

Dynavax developed the adjuvant to boost the immune response to its approved hepatitis B vaccine HEPLISAV-B.